Strategic Analysis of World Psychiatric Therapeutics Markets
Research Overview
Loss of Patent Protection Challenges Market Growth
The imminent patent expiration for key anticonvulsants such as Neurontin (in
2004), Topamax (in 2004), and Trileptal (in 2005) is expected to create a void
in the psychiatric therapeutics market. Apart from Lyrica
, lack of new anticonvulsants to counter the negative impact of patent
expiration is expected to magnify the challenge and expose the market to
competition from generic drugs. While patent expiration is not an issue in the
antipsychotics segment, pending patent protection for several products in this
segment is a major concern.
This Frost & Sullivan research evaluates the current state of the
psychiatric therapeutics market and examines the key drivers and challenges that
shape its current and future demand. This study highlights the important
research and development efforts in the top three psychiatric therapeutics
segments comprising anticonvulsants, antidepressants, and antipsychotics.
Huge Patient Population Drives Antidepressants Market Growth
An aging baby-boomer population has thrown open numerous opportunities in the
psychiatric therapeutics market, especially in the antidepressant segment.
Anxiety markets offer a lucrative proposition for continued expansion as
reflected in the growing acceptance and usage of antidepressants. "Over the
last few years, antidepressants have been witnessing greater acceptance among
the mainstream patient population ? Primarily due to effective direct to
consumer (DTC) marketing campaigns and the newly approved indications,"
says the analyst.
While the overall psychiatric therapeutics market is coming under intense
price pressure from governmental and insurance agencies, the prices of
antidepressant drugs have been rising steadily. Additionally, increasing uptake
of Cymbalta ? A recent introduction in the antidepressant segment ? Is expected
to minimize the negative impact of patent expiration and boost the total
revenues in the psychiatric therapeutics market.
Cost to Benefit Ratio of Atypical Antipsychotics Challenges Market
Expansion
The conversion from typical to atypical treatments has been a major driving
force in the antipsychotics segment. Not only are atypical antipsychotics more
expensive but studies have shown that, in terms of performance, these drugs
outstrip their typical counterparts. "However, in order to sustain growth
in the market and prove attractive to patients for long-term usage, researchers
need to pay serious attention to the cost-benefit ratio of atypical
antipsychotics," explains the analyst.
The increasing penetration of newer antipsychotics ? Such as Abilify have the
potential to provide benefits comparable to leading atypical antipsychotics
without causing the associated side effects. However, the newly approved
indications increase the use of atypical antipsychotics for treating bipolar
disorders and are likely to sustain revenues in the long run.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that provides
established and emerging firms with powerful growth visions. Moving beyond token
mission statements, GPS provides an actionable vision to growth consulting
partners by illustrating how key intelligence and strategic research based on
defined goals can guide day-to-day behavior and overall company direction. The
foundation of Frost & Sullivan's GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firm’s internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost &
Sullivan’s strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clients’ growth.
1 STRATEGIC ANALYSIS OF WORLD PSYCHIATRIC THERAPEUTICS MARKETS
- Overview
- Introduction
- Disclaimer
- Certification
- Research Scope and Methodology
- Study Objectives
- Market Segmentation by Geographical Region
- Market Segmentation by Indications
- Total Market Overview
- Market Dynamics Overview
- Research and Development Overview
- Executive Quote
- Anticonvulsant Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Demand Analysis
- Industry Challenges
- Market Drivers
- Market Restraints
- Revenue Potential
- Product Pipeline Analysis
- Product Analysis: Pregabalin
- Product Analysis: Rufinamide
- Antidepressants Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Demand Analysis
- Percent of Treated vs. Untreated Patients
- Industry Challenges
- Market Drivers
- Market Restraints
- Product Pipeline Analysis
- Product Analysis: Cymbalta
- Product Analysis: DVS-233 SR
- Product Analysis: Gepirone ER
- Product Analysis: SR 58611
- Antipsychotic Markets
- Introduction
- Revenues by Geographical Regions
- Revenue Forecast by Geographical Regions
- Revenue Split by Product
- Industry Challenges
- Market Drivers
- Market Restraints
- Product Pipeline Analysis
- CEO Quote
- Product Analysis: Bifeprunox
- Competitive Landscape
- Company Analysis
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Eli Lilly
- Johnson and Johnson
- Wyeth
- Novartis
- Forest Laboratories
- Organon
- Anticipating the Future
- Frost & Sullivan Awards
- Introduction
- Competitive Strategy Leadership Award
- Product Innovation Award - Antipsychotic Markets
- Product Innovation Award - Antidepressant Markets
- Growth Strategy Leadership Award
- Decision Support Databases
- Psychiatrics
- Neurologists
- Alzheimer's Patients
- Population 65 and Above
- Physicians
- Frost & Sullivan
- Healthcare Team
- Our Capabilities
- Key Advantages
- Our Consulting Clients
- Growth Consulting
- Growth Consulting Process
- Growth Consulting Deliverables
- Growth Partnership Service
- Growth Partnership Service Platform
医薬品
その他のカテゴリ
FAQ